Long-term Treatment of Teicoplanin for Methicillin-resistant Staphylococcus aureus Sternal Osteomyelitis with Renal Impairment: A Case of High Teicoplanin Trough Levels Maintained by Therapeutic Drug Monitoring
Teicoplanin, a glycopeptide antibiotic for methicillin-resistant Staphylococcus aureus, is recommended for therapeutic drug monitoring during treatment. Maintaining a high trough range of teicoplanin is also recommended for severe infectious disease. However, the optimal dose and interval of treatme...
Saved in:
| Published in | YAKUGAKU ZASSHI Vol. 136; no. 9; pp. 1313 - 1317 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
The Pharmaceutical Society of Japan
01.09.2016
Pharmaceutical Society of Japan |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0031-6903 1347-5231 |
| DOI | 10.1248/yakushi.15-00296 |
Cover
Loading…
| Abstract | Teicoplanin, a glycopeptide antibiotic for methicillin-resistant Staphylococcus aureus, is recommended for therapeutic drug monitoring during treatment. Maintaining a high trough range of teicoplanin is also recommended for severe infectious disease. However, the optimal dose and interval of treatment for severe renal impairment is unknown. We report a 79-year-old man who received long-term teicoplanin treatment for methicillin-resistant Staphylococcus aureus bacteremia due to postoperative sternal osteomyelitis with renal impairment. Plasma teicoplanin trough levels were maintained at a high range (20-30 μg/mL). Although the patient required long-term teicoplanin treatment, a further decline in renal function was not observed, and blood culture remained negative after the start of treatment. Teicoplanin treatment that is maintained at a high trough level by therapeutic drug monitoring might be beneficial for severe methicillin-resistant Staphylococcus aureus infection accompanied by renal impairment. |
|---|---|
| AbstractList | Teicoplanin, a glycopeptide antibiotic for methicillin-resistant Staphylococcus aureus, is recommended for therapeutic drug monitoring during treatment. Maintaining a high trough range of teicoplanin is also recommended for severe infectious disease. However, the optimal dose and interval of treatment for severe renal impairment is unknown. We report a 79-year-old man who received long-term teicoplanin treatment for methicillin-resistant Staphylococcus aureus bacteremia due to postoperative sternal osteomyelitis with renal impairment. Plasma teicoplanin trough levels were maintained at a high range (20-30 μg/mL). Although the patient required long-term teicoplanin treatment, a further decline in renal function was not observed, and blood culture remained negative after the start of treatment. Teicoplanin treatment that is maintained at a high trough level by therapeutic drug monitoring might be beneficial for severe methicillin-resistant Staphylococcus aureus infection accompanied by renal impairment. |
| Author | Higa, Futoshi Nakamura, Katsunori Shiohira, Hideo Kuniyoshi, Yukio Tateyama, Masao Fujita, Jiro Nakamatsu, Masashi Hokama, Nobuo Kise, Yuya Ueda, Shinichiro |
| Author_xml | – sequence: 1 fullname: Higa, Futoshi organization: Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus – sequence: 1 fullname: Nakamura, Katsunori organization: Department of Hospital Pharmacy, Faculty of Medicine, University of the Ryukyus – sequence: 1 fullname: Shiohira, Hideo organization: Infection Control Room, University of the Ryukyus Hospital – sequence: 1 fullname: Kise, Yuya organization: Department of Thoracic and Cardiovascular Surgery, Graduate School of Medicine, University of the Ryukyus – sequence: 1 fullname: Fujita, Jiro organization: Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus – sequence: 1 fullname: Ueda, Shinichiro organization: Department of Clinical Pharmacology and Therapeutics, Graduate School of Medicine, University of the Ryukyus – sequence: 1 fullname: Tateyama, Masao organization: Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus – sequence: 1 fullname: Kuniyoshi, Yukio organization: Department of Thoracic and Cardiovascular Surgery, Graduate School of Medicine, University of the Ryukyus – sequence: 1 fullname: Nakamatsu, Masashi organization: Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus – sequence: 1 fullname: Hokama, Nobuo organization: Department of Hospital Pharmacy, Faculty of Medicine, University of the Ryukyus |
| BookMark | eNpVUV1r3DAQFCWFXtO891F_wKklnfzRt3Btc4E7Ao37LPbkta2rLR2S3OK_2V9UOQmFCrQD0uwMu_OeXFlnkZCPLL9lfFt9WuDnHAZzy2SW57wu3pANE9syk1ywK7LJc8Gyos7FO3ITgjklTjqSVRvy5-Bsn0X0E208QpzQRuo62qDR7jKCNZZ2ztMjxsFoM47GZh6DCRES8SnCZVhGp53Wc6Awe0zwlOQsjPQxRHTTgqOJJtDfJg70O64fD9MFjF-tPtM7uoOAq-Xe9MN_vo13c3o64C8cAz2CsTFdbOlpoc2AHi44R6PpFz_39Oisic4b238gbzsYA9684jX58e1rs9tnh8f7h93dITsLLkQm2op3DGTVyhJbzjpZdVxiqWtZtqB5VyMrGZcSJLYnsUXQ9baqiu6kZSUqJq7J_YvuhK3RMDqbloPq7OZ1-qB0KNdcesVzVqiciSKvEzDFBBNrKXnJC8aLpLR_UTqntfaoLt5M4BcFPo03onqNN_UUqn6uTKrnoP9R9ABeoRV_AUP9qkM |
| ContentType | Journal Article |
| Copyright | 2016 The Pharmaceutical Society of Japan |
| Copyright_xml | – notice: 2016 The Pharmaceutical Society of Japan |
| CorporateAuthor | University of the Ryukyus Hospital cDepartment of Infectious bInfection Control Room aDepartment of Hospital Pharmacy Faculty of Medicine eDepartment of Clinical Pharmacology and Therapeutics Graduate School of Medicine Respiratory University of the Ryukyus dDepartment of Thoracic and Cardiovascular Surgery and Digestive Medicine |
| CorporateAuthor_xml | – name: Faculty of Medicine – name: University of the Ryukyus – name: dDepartment of Thoracic and Cardiovascular Surgery – name: cDepartment of Infectious – name: University of the Ryukyus Hospital – name: Graduate School of Medicine – name: eDepartment of Clinical Pharmacology and Therapeutics – name: bInfection Control Room – name: Respiratory – name: and Digestive Medicine – name: aDepartment of Hospital Pharmacy |
| DOI | 10.1248/yakushi.15-00296 |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1347-5231 |
| EndPage | 1317 |
| ExternalDocumentID | cs7yakug_2016_013609_011_1313_13172726126 article_yakushi_136_9_136_15_00296_article_char_en |
| GroupedDBID | .55 123 29R 2WC ADBBV ALMA_UNASSIGNED_HOLDINGS BAWUL CS3 DIK E3Z EBS EJD F5P GX1 HH5 JMI JSF JSH MOJWN OVT P2P RJT RNS RZJ X7M XSB |
| ID | FETCH-LOGICAL-j3233-3d82f1a58d57ed21f58f25e7c957dac2f9e171255a5edb34eac94886fbc583813 |
| ISSN | 0031-6903 |
| IngestDate | Thu Jul 10 16:10:25 EDT 2025 Wed Sep 03 06:23:44 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j3233-3d82f1a58d57ed21f58f25e7c957dac2f9e171255a5edb34eac94886fbc583813 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/yakushi/136/9/136_15-00296/_article/-char/en |
| PageCount | 5 |
| ParticipantIDs | medicalonline_journals_cs7yakug_2016_013609_011_1313_13172726126 jstage_primary_article_yakushi_136_9_136_15_00296_article_char_en |
| PublicationCentury | 2000 |
| PublicationDate | 20160901 |
| PublicationDateYYYYMMDD | 2016-09-01 |
| PublicationDate_xml | – month: 09 year: 2016 text: 20160901 day: 01 |
| PublicationDecade | 2010 |
| PublicationTitle | YAKUGAKU ZASSHI |
| PublicationTitleAlternate | YAKUGAKU ZASSHI |
| PublicationYear | 2016 |
| Publisher | The Pharmaceutical Society of Japan Pharmaceutical Society of Japan |
| Publisher_xml | – name: The Pharmaceutical Society of Japan – name: Pharmaceutical Society of Japan |
| References | 14) Hayakawa T., Kishimoto H., Takino A., Nakagawa H., Shibata N., Takada K., Monden T., Jpn. J. Ther. Drug Monit., 18, 328-336 (2001). 2) Nathwani D., Morgan M., Masterton R. G., Dryden M., Cookson B. D., French G., Lewis D., British Society for Antimicrobial Chemotherapy Working Party on Community-onset MRSA Infections, J. Antimicrob. Chemother., 61, 976-994 (2008). 15) Cornely O. A., Lasso M., Betts R., Klimko N., Vazquez J., Dobb G., Velez J., Williams-Diaz A., Lipka J., Taylor A., Sable C., Kartsonis N., J. Antimicrob. Chemother., 60, 363-369 (2007). 12) Brink A. J., Richards G. A., Cummins R. R., Lambson J., Gauteng Understanding Teicoplanin Serum levels (GUTS) study group, Int. J. Antimicrob. Agents, 32, 455-458 (2008). 1) Takesue Y., Watanabe A., Hanaki H., Kusachi S., Matsumoto T., Iwamoto A., Totsuka K., Sunakawa K., Yagisawa M., Sato J., Oguri T., Nakanishi K., Sumiyama Y., Kitagawa Y., Wakabayashi G., Koyama I., Yanaga K., Konishi T., Fukushima R., Seki S., Imai S., Shintani T., Tsukada H., Tsukada K., Omura K., Mikamo H., Takeyama H., Kusunoki M., Kubo S., Shimizu J., Hirai T., Ohge H., Kadowaki A., Okamoto K., Yanagihara K., J. Infect. Chemother., 18, 816-826 (2012). 7) Goto H., Shimada K., Ikemoto H., Oguri T., Study Group on Antimicrobial Susceptibility of Pathogens Isolated from Respiratory Infections, J. Infect. Chemother., 15, 347-360 (2009). 4) Svetitsky S., Leibovici L., Paul M., Antimicrob. Agents Chemother., 53, 4069-4079 (2009). 6) MacGowan A. P., Ther. Drug Monit., 20, 473-477 (1998). 9) Harding I., MacGowan A. P., White L. O., Darley E. S., Reed V., J. Antimicrob. Chemother., 45, 835-841 (2000). 5) Wilson A. P., Clin. Pharmacokinet., 39, 167-183 (2000). 13) Ueda T., Takesue Y., Nakajima K., Ichki K., Wada Y., Tsuchida T., Takahashi Y., Ishihara M., Tatsumi S., Kimura T., Ikeuchi H., Uchino M., J. Infect. Chemother., 18, 296-302 (2012). 16) Betts R. F., Nucci M., Talwar D., Gareca M., Queiroz-Telles F., Bedimo R. J., Herbrecht R., Ruiz-Palacios G., Young J. A., Baddley J. W., Strohmaier K. M., Tucker K. A., Taylor A. F., Kartsonis N. A., Caspofungin High-Dose Study Group, Clin. Infect. Dis., 48, 1676-1684 (2009). 11) Dong Y. L., Dong H. Y., Hu S. S., Wang X., Wei Y. X., Wang M. Y., Dong W. H., Yao H. P., You H. S., Xing J. F., Int. J. Clin. Pharmacol. Ther., 49, 14-22 (2011). 3) Yoshida M., Matzno S., Namba H., Nishikata M., Matsuyama K., J. Infect. Chemother., 12, 114-118 (2006). 8) Kunishima H., Yamamoto N., Kobayashi T., Minegishi M., Nakajima S., Chiba J., Kitagawa M., Hirakata Y., Honda Y., Kaku M., J. Infect. Chemother., 16, 414-417 (2010). 10) Matsumoto K., Kanazawa N., Ikawa K., Fukamizu T., Shigemi A., Yaji K., Shimodozono Y., Morikawa N., Takeda Y., Yamada K., J. Infect. Chemother., 16, 193-199 (2010). |
| References_xml | – reference: 6) MacGowan A. P., Ther. Drug Monit., 20, 473-477 (1998). – reference: 10) Matsumoto K., Kanazawa N., Ikawa K., Fukamizu T., Shigemi A., Yaji K., Shimodozono Y., Morikawa N., Takeda Y., Yamada K., J. Infect. Chemother., 16, 193-199 (2010). – reference: 12) Brink A. J., Richards G. A., Cummins R. R., Lambson J., Gauteng Understanding Teicoplanin Serum levels (GUTS) study group, Int. J. Antimicrob. Agents, 32, 455-458 (2008). – reference: 7) Goto H., Shimada K., Ikemoto H., Oguri T., Study Group on Antimicrobial Susceptibility of Pathogens Isolated from Respiratory Infections, J. Infect. Chemother., 15, 347-360 (2009). – reference: 8) Kunishima H., Yamamoto N., Kobayashi T., Minegishi M., Nakajima S., Chiba J., Kitagawa M., Hirakata Y., Honda Y., Kaku M., J. Infect. Chemother., 16, 414-417 (2010). – reference: 4) Svetitsky S., Leibovici L., Paul M., Antimicrob. Agents Chemother., 53, 4069-4079 (2009). – reference: 1) Takesue Y., Watanabe A., Hanaki H., Kusachi S., Matsumoto T., Iwamoto A., Totsuka K., Sunakawa K., Yagisawa M., Sato J., Oguri T., Nakanishi K., Sumiyama Y., Kitagawa Y., Wakabayashi G., Koyama I., Yanaga K., Konishi T., Fukushima R., Seki S., Imai S., Shintani T., Tsukada H., Tsukada K., Omura K., Mikamo H., Takeyama H., Kusunoki M., Kubo S., Shimizu J., Hirai T., Ohge H., Kadowaki A., Okamoto K., Yanagihara K., J. Infect. Chemother., 18, 816-826 (2012). – reference: 3) Yoshida M., Matzno S., Namba H., Nishikata M., Matsuyama K., J. Infect. Chemother., 12, 114-118 (2006). – reference: 15) Cornely O. A., Lasso M., Betts R., Klimko N., Vazquez J., Dobb G., Velez J., Williams-Diaz A., Lipka J., Taylor A., Sable C., Kartsonis N., J. Antimicrob. Chemother., 60, 363-369 (2007). – reference: 11) Dong Y. L., Dong H. Y., Hu S. S., Wang X., Wei Y. X., Wang M. Y., Dong W. H., Yao H. P., You H. S., Xing J. F., Int. J. Clin. Pharmacol. Ther., 49, 14-22 (2011). – reference: 2) Nathwani D., Morgan M., Masterton R. G., Dryden M., Cookson B. D., French G., Lewis D., British Society for Antimicrobial Chemotherapy Working Party on Community-onset MRSA Infections, J. Antimicrob. Chemother., 61, 976-994 (2008). – reference: 9) Harding I., MacGowan A. P., White L. O., Darley E. S., Reed V., J. Antimicrob. Chemother., 45, 835-841 (2000). – reference: 16) Betts R. F., Nucci M., Talwar D., Gareca M., Queiroz-Telles F., Bedimo R. J., Herbrecht R., Ruiz-Palacios G., Young J. A., Baddley J. W., Strohmaier K. M., Tucker K. A., Taylor A. F., Kartsonis N. A., Caspofungin High-Dose Study Group, Clin. Infect. Dis., 48, 1676-1684 (2009). – reference: 14) Hayakawa T., Kishimoto H., Takino A., Nakagawa H., Shibata N., Takada K., Monden T., Jpn. J. Ther. Drug Monit., 18, 328-336 (2001). – reference: 5) Wilson A. P., Clin. Pharmacokinet., 39, 167-183 (2000). – reference: 13) Ueda T., Takesue Y., Nakajima K., Ichki K., Wada Y., Tsuchida T., Takahashi Y., Ishihara M., Tatsumi S., Kimura T., Ikeuchi H., Uchino M., J. Infect. Chemother., 18, 296-302 (2012). |
| SSID | ssib002222518 ssib002484306 ssib001136365 ssib002223935 ssib002484304 ssib002484305 ssib000959844 ssib002822080 ssib003105265 ssib023161479 ssj0023355 ssib000576198 ssib002499502 ssib003105266 ssib000937675 ssib000972830 ssib001536036 ssib002222551 ssib058494605 ssib058494604 |
| Score | 2.1379488 |
| Snippet | Teicoplanin, a glycopeptide antibiotic for methicillin-resistant Staphylococcus aureus, is recommended for therapeutic drug monitoring during treatment.... |
| SourceID | medicalonline jstage |
| SourceType | Publisher |
| StartPage | 1313 |
| SubjectTerms | bacteremia methicillin-resistant Staphylococcus aureus renal impairment teicoplanin therapeutic drug monitoring |
| Title | Long-term Treatment of Teicoplanin for Methicillin-resistant Staphylococcus aureus Sternal Osteomyelitis with Renal Impairment: A Case of High Teicoplanin Trough Levels Maintained by Therapeutic Drug Monitoring |
| URI | https://www.jstage.jst.go.jp/article/yakushi/136/9/136_15-00296/_article/-char/en http://mol.medicalonline.jp/library/journal/download?GoodsID=cs7yakug/2016/013609/011&name=1313-1317e |
| Volume | 136 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | YAKUGAKU ZASSHI, 2016/09/01, Vol.136(9), pp.1313-1317 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEI7ackFCiKcoL_mAetmm3cSxs-bEqlC2D6CiW6nlEiWO092WJtVmc1h-Jr-ImdhNnFUPFHFYZ52Xk4z9-ZvxeOw47wYSai6TnpuGoKIEIuXuQCiFDU9KGQjKk9rL9ysfnQT7p-x0ZXXb8lqq5smW_HXrvJJ_kSrsA7niLNk7SLa5KeyA_yBfSEHCkP6VjA-L_NxFbO2NG39xIH9jBeK9_hlj3FT0Ivyi0KkdDSu5C9o1MkY4EWgmfGLoywopq7IXVzMFm2MdFLr3DaRfXC0UeseZGXDfFR7YA_yYzhqbYm8nNqMBoOV3Sh7rBYAO0SupRF-OHK0QmvCO21lfvY-z6txAy-ymHzVs-Wx4cPIZfr0fw-PjUWPfhaJqyrtbzYtyMm3s2fFlfFXNzBy3eVnlcMPGgjSZFpOpPjiapqponQ_00pJn1SK2TSAeb3y8dKXFBnU06YwA3Li8wuvvA-nI7S6Aei4XfY2qSqM-DULUyL1Ot6ADs5j6LyyQ96hHLcIA2fDWzsgPcILFIr6s4FtseczFIdCluN81kzAVKDKnRlB0JOrUY1F9UXRzCs7Fg6q_6tzzw1D7JewdWPwbrVIWvxZLwXoEEwN7uQMRYgC4lj9DmZTb8fsoB4pj8T2Af4vM1HlrWBnJpqCdeHkBtfX9Or983Lo_6N-s3xnm9_tWBwO6SGc5B51vrgcJAttsh52BXIvACj5k8m0wTkqZXuLE1AnjxwCPtb0sNmCoF9A8MRDHgys9hqpj2Vh0dPzIeWj0SDLUAnvsrFzET5wNUz8Xm8RqYeUm2SBHbYj6xVPnd4McpEEOUmTEar8EkIPcihykixxEIwcxyEE6yEEQOUiNHKRFjvdkSBA3sEjEjU65GjeIxg3S4gZJFvZbEcQN0uLGM-dk99N4Z-Sa1V3cCwof3qXpwM-8mA1SFqrU9zI2yHymQilYmMbSz4TyQlC_WMxUmtAAGKIAtsGzRKKrh0efO2t5kasXDhFcyLTPBY1BweIZT4TIBA8VzQIl_L5cd4ZadtG1DuET3b3FrTsfOmKPTD9QRrIM8TbnEUJThDEw-wI2XoQ4gQn6uoAiyV_-h8d45dxvEfC1szafVeoNqEXz5G0NBX8A-V9SPQ |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+Treatment+of+Teicoplanin+for+Methicillin-resistant+Staphylococcus+aureus+Sternal+Osteomyelitis+with+Renal+Impairment%3A+A+Case+of+High+Teicoplanin+Trough+Levels+Maintained+by+Therapeutic+Drug+Monitoring&rft.jtitle=YAKUGAKU+ZASSHI&rft.au=Higa%2C+Futoshi&rft.au=Nakamura%2C+Katsunori&rft.au=Shiohira%2C+Hideo&rft.au=Kise%2C+Yuya&rft.date=2016-09-01&rft.pub=The+Pharmaceutical+Society+of+Japan&rft.issn=0031-6903&rft.eissn=1347-5231&rft.volume=136&rft.issue=9&rft.spage=1313&rft.epage=1317&rft_id=info:doi/10.1248%2Fyakushi.15-00296&rft.externalDocID=article_yakushi_136_9_136_15_00296_article_char_en |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0031-6903&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0031-6903&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0031-6903&client=summon |